Analyst: Science Stock Sports Long-Term Support

Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 2% in pre-market trading, after Raymond James upgraded the stock to "outperform" from "market perform."  According to the the brokerage, GILD -- one of Schaeffer's top 2024 picks -- has support over the next five years from two key drug candidates that could increase revenue growth.Overall, analysts are pessimistic towards toward the security, with 14 of 24 covering firms recommending a "hold," and the stock's average 12-month price target stand ...